Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
CONCLUSION This study demonstrates the induction of NK cell effector functions early after Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation and regulation of NK cells by Ebola glycoprotein.TRIAL REGISTRATION ClinicalTrials.gov NCT02313077.FUNDING United Kingdom Medical Research Council Studentship in Vaccine Research, Innovative Medicines Initiative 2 Joint Undertaking, EBOVAC (grant 115861) and Crucell Holland (now Janssen Vaccines and Prevention B.V.), European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Helen R. Wagstaffe, Elizabeth A. Clutterbuck, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D. Snape, Andrew J. Pollard, Eleanor M. Riley, Martin R. Goodier Source Type: research
More News: Adenoviruses | Biomedical Science | Ebola | Ebola Vaccine | Grants | Research | Study | UK Health | Universities & Medical Training | Vaccines